Login to Your Account



FDA Panel Narrowly Backs Dyax's HAE Drug Kalbitor

By Donna Young


Thursday, February 5, 2009
GAITHERSBURG, Md. - A panel of experts Wednesday narrowly backed the approval of Dyax Corp.'s Kalbitor (ecallantide, DX-88) to treat acute attacks of hereditary angioedema (HAE), a rare, genetic disorder, despite the drug's potential to cause severe allergic reactions and a lack of robust study data. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription